ERBB2 and breast carcinoma: In a preliminary experiment, we found that all three Fc-fusion proteins were able to potently inhibit the proliferation of the HER2-overexpressing human breast cancer cell line SKBR3 in a dose-dependent manner with SMET2.1Fc having the highest inhibitory activity (Figure S1).